CAS 85721-33-1 Antibacterial Raw Material Antimicrobial Ciprofloxacin C17H18FN3O3

CAS 85721-33-1 Antibacterial Raw Material Antimicrobial Ciprofloxacin

The Introductction of Ciprofloxacin:

Ciprofloxacin for synthesis of the third generation quinolone antibacterial drugs, with broad-spectrum antibacterial activity, bactericidal effect is good, for almost all bacteria antimicrobial activity of norfloxacin and in accordance with the strong effect of 2 ~ 4 times, for e. coli, pseudomonas aeruginosa, h. influenzae, neisseria gonorrhoeae, legionella bacteria, staphylococcus aureus, streptococcus has antibacterial effect.

The Application & Function of ​Ciprofloxacin:

1.Ciprofloxacin HCl drug is used for the treatment of Bacterial infection of Respiratory tract, UTI, Uncomplicated Cystitis in females, GI, Chronic Bacterial Prostatitis, CNS, Immuno compromised patients, Skin, Bone and Joint Infections, Uncomplicated cervical and urethral gonorrhea.

2.Ciprofloxacin HCl drug has in vitro activity against a wide range of gram-negative and gram-positive organisms. Ciprofloxacin HCl drug inhibits bacterial DNA gyrase, an enzyme responsible for counteracting excessive supercoiling of DNA during replication or transcription. The mechanism of action of quinolones, including Ciprofloxacin HCl drug, is different from that of other antimicrobial agents; therefore, organisms resistant to these drugs may be susceptible to Ciprofloxacin HCl drug. There is no known cross-resistance between ciprofloxacin HCl drug and other classes of antimicrobials.

3.Ciprofloxacin is used to treat a wide variety of infections, including infections of bones and joints, endocarditis, gastroenteritis, malignant otitis externa, respiratory tract infections, cellulitis, urinary tract infections,prostatitis, anthrax, and chancroid.

4.Ciprofloxacin only treats bacterial infections; it does not treat viral infections such as the common cold. For certain uses including acute sinusitis, lower respiratory tract infections and uncomplicated gonorrhea, ciprofloxacin is not considered a first-line agent.

5.Ciprofloxacin occupies an important role in treatment guidelines issued by major medical societies for the treatment of serious infections, especially those likely to be caused by Gram-negative bacteria, including Pseudomonas aeruginosa. For example, ciprofloxacin in combination with metronidazole is one of several first-line antibiotic regimens recommended by the Infectious Diseases Society of America for the treatment of community-acquired abdominal infections in adults.It also features prominently in treatment guidelines for acute pyelonephritis, complicated or hospital-acquired urinary tract infection, acute or chronic prostatitis,certain types of endocarditis, certain skin infections, and prosthetic joint infections.

The COA of ​Ciprofloxacin: